CL2011001592A1 - Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08). - Google Patents

Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08).

Info

Publication number
CL2011001592A1
CL2011001592A1 CL2011001592A CL2011001592A CL2011001592A1 CL 2011001592 A1 CL2011001592 A1 CL 2011001592A1 CL 2011001592 A CL2011001592 A CL 2011001592A CL 2011001592 A CL2011001592 A CL 2011001592A CL 2011001592 A1 CL2011001592 A1 CL 2011001592A1
Authority
CL
Chile
Prior art keywords
encodes
binds
human
production
pharmaceutical composition
Prior art date
Application number
CL2011001592A
Other languages
English (en)
Inventor
Heinz Heider Karl
Borges Eric
Ostermann Elinborg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2011001592A1 publication Critical patent/CL2011001592A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Molécula de anticuerpo que se une a CD37 humano; molécula de ADN que lo codifica; vector; célula anfitriona; método de producción; composición farmacéutica que lo comprende; y método para suprimir células B que expresan CD37. (DIV.2349-08)
CL2011001592A 2007-08-09 2011-06-24 Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08). CL2011001592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114128 2007-08-09

Publications (1)

Publication Number Publication Date
CL2011001592A1 true CL2011001592A1 (es) 2012-02-17

Family

ID=38925567

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008002349A CL2008002349A1 (es) 2007-08-09 2008-08-08 Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
CL2011001592A CL2011001592A1 (es) 2007-08-09 2011-06-24 Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08).
CL2012002329A CL2012002329A1 (es) 2007-08-09 2012-08-22 Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2008002349A CL2008002349A1 (es) 2007-08-09 2008-08-08 Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2012002329A CL2012002329A1 (es) 2007-08-09 2012-08-22 Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08)

Country Status (37)

Country Link
US (7) US20100189722A1 (es)
EP (3) EP2178915B1 (es)
JP (3) JP5325216B2 (es)
KR (1) KR101593403B1 (es)
CN (4) CN105273086A (es)
AR (2) AR071242A1 (es)
AU (1) AU2008285590B2 (es)
BR (2) BRPI0815369A2 (es)
CA (1) CA2693464C (es)
CL (3) CL2008002349A1 (es)
CO (1) CO6251371A2 (es)
CY (1) CY1117101T1 (es)
DK (1) DK2178915T3 (es)
EA (2) EA027499B1 (es)
EC (2) ECSP109946A (es)
ES (1) ES2555202T3 (es)
HK (1) HK1220708A1 (es)
HR (1) HRP20160009T1 (es)
HU (1) HUE026221T2 (es)
IL (1) IL202645A (es)
MA (1) MA32665B1 (es)
ME (1) ME02300B (es)
MY (1) MY157555A (es)
NZ (2) NZ583713A (es)
PE (3) PE20090499A1 (es)
PH (1) PH12014501812A1 (es)
PL (1) PL2178915T3 (es)
PT (1) PT2178915E (es)
RS (1) RS54359B1 (es)
SG (1) SG190657A1 (es)
SI (1) SI2178915T1 (es)
TN (1) TN2010000068A1 (es)
TW (2) TWI535733B (es)
UA (2) UA105445C2 (es)
UY (1) UY31275A1 (es)
WO (1) WO2009019312A2 (es)
ZA (1) ZA200908758B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2011076922A1 (en) * 2009-12-23 2011-06-30 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
NO331080B1 (no) 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
DK2544719T3 (da) 2010-03-12 2019-10-14 Debiopharm Int Sa Cd37-bindingsmolekyler og immunkonjugater deraf
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20120107317A1 (en) * 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
BR112013025208A2 (pt) * 2011-04-01 2018-09-11 Immunogen Inc moléculas de ligação a cd-37 e imunoconjugados das mesmas
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
EP3272364B1 (en) * 2011-12-13 2020-07-29 Nordic Nanovector ASA Chimeric therapeutic anti-cd37 antibodie hh1
KR20140143810A (ko) * 2012-03-30 2014-12-17 이뮤노젠 아이엔씨 Cd37 기반 치료의 효과를 증대시키는 방법
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
WO2013171289A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
EP3008089A1 (en) * 2013-06-14 2016-04-20 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with chlorambucil
EP3027220A1 (en) 2013-08-01 2016-06-08 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
US9291244B2 (en) 2014-01-17 2016-03-22 Ford Global Technologies, Llc Nine speed automatic transmission
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
KR102492532B1 (ko) 2015-05-29 2023-01-30 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
EP3302561A4 (en) 2015-06-08 2019-02-06 Debiopharm International SA COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES
SI3124976T1 (sl) 2015-07-28 2018-12-31 F. Hoffmann-La Roche Ag Izboljšan test bakterijskih endotoksinov za določanje endotoksinov
KR20180042423A (ko) 2015-08-28 2018-04-25 데비오팜 인터네셔날 에스 에이 Cd37 의 검출을 위한 항체 및 검정
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
ES2963226T3 (es) * 2016-12-07 2024-03-26 Agenus Inc Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3595721A4 (en) 2017-03-16 2021-01-06 The General Hospital Corporation CHEMERICAL ANTIGEN RECEPTORS TARGETING CD37
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
US11696572B2 (en) * 2017-06-27 2023-07-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ASGR1 locus
EP3810194A1 (en) 2018-06-22 2021-04-28 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
CA3099928A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
AU2020336440A1 (en) * 2019-08-30 2022-03-24 Qilu Puget Sound Biotherapeutics Corporation Anti-CD20 antibodies, anti-CD37 antibodies, and mixtures thereof
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
AU2022368385A1 (en) * 2021-10-18 2024-04-11 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
CA1341351C (en) * 1988-09-06 2002-03-26 Marc D. Better Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0393438B1 (de) 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE122006000006I2 (de) 1991-08-14 2011-06-16 Genentech Inc Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1242401B1 (en) 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
EP1534336A4 (en) 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
EP2042517B1 (en) 2002-09-27 2012-11-14 Xencor, Inc. Optimized FC variants and methods for their generation
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
CA2930485C (en) 2003-05-14 2018-04-10 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
CN103351434B (zh) 2004-07-15 2015-09-30 赞科股份有限公司 优化的Fc变体
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
DK2298815T3 (en) * 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
BRPI0814060A2 (pt) 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2318048B1 (en) 2008-07-21 2019-05-29 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
BRPI0921006A2 (pt) 2008-11-13 2015-12-15 Emergent Product Dev Seattle terapias imunoterapêuticas combinadas de cd37 e usos destas
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171289A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
WO2013171287A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
EP3008089A1 (en) 2013-06-14 2016-04-20 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with chlorambucil

Also Published As

Publication number Publication date
AU2008285590A1 (en) 2009-02-12
TW200916478A (en) 2009-04-16
WO2009019312A3 (en) 2009-04-30
PE20090499A1 (es) 2009-05-18
TW201512220A (zh) 2015-04-01
EA201200994A1 (ru) 2012-12-28
ES2555202T3 (es) 2015-12-29
CL2008002349A1 (es) 2009-10-23
DK2178915T3 (en) 2015-12-14
ME02300B (me) 2016-06-20
IL202645A (en) 2016-03-31
RS54359B1 (en) 2016-04-28
CN103396490A (zh) 2013-11-20
PT2178915E (pt) 2016-02-04
US9932399B2 (en) 2018-04-03
KR101593403B1 (ko) 2016-02-12
US20100189722A1 (en) 2010-07-29
US20180186876A1 (en) 2018-07-05
MA32665B1 (fr) 2011-10-02
EA201000274A1 (ru) 2010-10-29
PH12014501812B1 (en) 2016-10-24
UA103005C2 (en) 2013-09-10
KR20100054791A (ko) 2010-05-25
SI2178915T1 (sl) 2016-01-29
ECSP11009946A (es) 2011-09-30
HRP20160009T1 (hr) 2016-02-12
PE20120259A1 (es) 2012-04-04
CL2012002329A1 (es) 2012-12-21
US9078879B2 (en) 2015-07-14
MY157555A (en) 2016-06-30
JP2014039541A (ja) 2014-03-06
NZ600022A (en) 2013-11-29
BRPI0815369A2 (pt) 2013-03-12
CN101815725A (zh) 2010-08-25
US20110165153A1 (en) 2011-07-07
AU2008285590B2 (en) 2014-08-14
TN2010000068A1 (en) 2011-09-26
TWI535733B (zh) 2016-06-01
US20140010808A1 (en) 2014-01-09
JP2011004758A (ja) 2011-01-13
CA2693464C (en) 2017-10-24
SG190657A1 (en) 2013-06-28
UA105445C2 (en) 2014-05-12
JP5325216B2 (ja) 2013-10-23
CY1117101T1 (el) 2017-04-05
ZA200908758B (en) 2010-08-25
CN105273086A (zh) 2016-01-27
UY31275A1 (es) 2009-03-31
JP2010535483A (ja) 2010-11-25
EP2562187A1 (en) 2013-02-27
WO2009019312A2 (en) 2009-02-12
AR107902A2 (es) 2018-06-28
EP2241577A1 (en) 2010-10-20
AR071242A1 (es) 2010-06-09
EP2178915A2 (en) 2010-04-28
CN102276724A (zh) 2011-12-14
ECSP109946A (es) 2010-04-30
EP2562187B1 (en) 2019-03-27
HUE026221T2 (en) 2016-05-30
PH12014501812A1 (en) 2016-10-24
IL202645A0 (en) 2011-08-01
US20140004110A1 (en) 2014-01-02
BRPI0823331A2 (pt) 2013-07-30
CO6251371A2 (es) 2011-02-21
HK1220708A1 (zh) 2017-05-12
EP2178915B1 (en) 2015-10-14
NZ583713A (en) 2012-07-27
PE20140196A1 (es) 2014-03-19
CA2693464A1 (en) 2009-02-12
US20160137729A1 (en) 2016-05-19
US20210230271A1 (en) 2021-07-29
PL2178915T3 (pl) 2016-03-31
EA027499B1 (ru) 2017-08-31
JP5238000B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
CL2011001592A1 (es) Anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celulas huesped; metodo de produccion; composicion farmaceutica que lo comprende (divisional de la solicitud 2348-08).
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
CL2011001503A1 (es) Proteina de enlace a antigeno que se enlaza especificamente a miostatina; molecula de acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad que reduzca masa muscular, fuerza muscular y funcion muscular.
CL2014001334A1 (es) Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006).
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
CL2012003196A1 (es) Anticuerpo aislado o fragmento del mismo que se une específicamente a interleuquina-4 (il-4); molécula de ácido nucleico aislado que lo codifica y vector que la comprende; célula que comprende dicho vector; composición farmacéutica que comprende dicho anticuerpo; y su uso parar tratar una enfermedad alérgica, cáncer y asma.
CL2013000019A1 (es) Proteina fijadora de antigeno aislada que fija el factor de crecimiento epidermico fijador de heparina (hg-egf); molecula de acido nucleico que la codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad hiperproliferativa.
CL2017000772A1 (es) Anticuerpo aislado que se une a mesotelina; ácido nucleico que lo codifica; célula huésped; método de producción; inmunoconjugado; formulación farmacéutica que lo comprende; su uso para tratar cáncer; y método de detección de mesotelina humana. (divisional solicitud 1776-2013)
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
CL2008001814A1 (es) Anticuerpos anti-factor de crecimiento 1 y 2 semejantes a insulina (igf-1, igf-2); molecula de adn que los codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que los comprende; y su uso para tratar cancer.
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
CL2011000672A1 (es) Anticuerpo que se une a il-17 humana; acido nucleico que lo codifica; vector de expresion; linea celular; metodo de produccion; composicion farmaceutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades.
BRPI0610197B8 (pt) anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2016002116A1 (es) Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13).
CL2013000669A1 (es) Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
CL2008002856A1 (es) Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
CL2011000308A1 (es) Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune.
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
MX2009005776A (es) Anticuerpos humanos que se enlazan al cd 22 y sus usos.